Contra-indicated in patients with complete biliary obstruction.
- TRADE NAME: Ocaliva (Intercept)
- INDICATIONS: Primary biliary cholangitis
- CLASS: Farnesoid X receptor (FXR) agonist
- HALF-LIFE: N/A
- FDA APPROVAL DATE: 05/27/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aminophylline, Tizanidine, Warfarin - PREGNANCY: Insufficient evidence to inform drug-associated risk
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
